Myeloproliferative Neoplasms
MANIFEST-2 compares pelabresib plus ruxolitinib with placebo plus ruxolitinib for JAK-inhibitor-naive disease.
While cytoreductive drugs did not reduce thrombosis risk, interferon significantly improved myelofibrosis-free survival.
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
The agent targets abnormal gene expression in order to control the excessive cell proliferation that occurs in PV.
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
Investigational T-Cell Immunotherapy Superior to Standard HSCT in Rate of Survival Plus GvHD Freedom
A phase 3 study comparing the treatments in multiple hematologic malignancies also saw greater overall survival at one year.
The hepcidin mimetic increased hematocrit control and reduced both phlebotomy need and symptoms in a phase 2 trial.
Thrombosis history was not predictive of overall survival in patients with pulmonary hypertension risk and PV, a study found.
The panel's discussion, moderated by Neil Love, MD, dove especially into the nuances of using avapritinib and ruxolitinib.
Advertisement
Expert Interviews on Hematology
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.